1184844-74-3

17(R),18(S)-Epoxyeicosatetraenoic acid (17(R),18(S)-EpETE), a natural cytochrome P450 epoxygenase metabolite of eicosapentaenoic acid, is known to reduce the contraction rate of spontaneously beating heart cells and to protect neonatal rat cardiomyocytes against arrhythmias induced by β-adrenergic agonists (EC₅₀ = ~ 1-2 nM).¹ CAY10662 is a 1,3 disubstituted urea derivative of 17(R),18(S)-EpETE that is more metabolically robust and reduces the contractility of cardiomyocytes with improved potency (EC₅₀ < 1 nM) over its parent compound.¹ At concentrations 1,000-fold higher than required for the effect on cardiomyocytes, 1-5 μM CAY10662 exerts weak dose-dependent soluble epoxide hydrolase inhibition.¹

(Z)-16-(Ethylcarbamoylamino)hexadec-11-enoic acid (Compound 21) is a vasorelaxant (EC50=5.7 μM) that can be used in cardiovascular disease research[1].

1. Falck, J.R., Wallukat, G., Puli, N., et al. 17(R),18(S)-Epoxyeicosatetraenoic acid, a potent eicosapentaenoic acid (EPA) derived regulator of cardiomyocyte contraction: Structure-activity relationships and stable analogues J. Med. Chem. 54(12),4109-4118(2011).